GRAIL Inc

GRAL

Market cap $3.09B

Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Conditions Samsung C&T Will Drive Commercialization of Galleri in South Korea With Possible Expansion to Japan and Singapore Samsung Electronics and GRAIL Will Also Explore Potential Strategic and Operational Collaborations SEOUL, Korea and MENLO PARK, Calif. , Oct. 16, 2025 /PRNewswire/ -- Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (Nasdaq: GRAL), today announced they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL's GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets.

Grail, Inc. represents a speculative long-term investment opportunity, conditional on the FDA's approval of its Galleri multi-cancer early detection blood test and its widespread adoption among the general population. Assuming FDA approval, GRAL could reach $100–$250 per share, based on reasonable assumptions regarding its total addressable market and the prevailing competitive landscape. Galleri's robust revenue growth as a predominantly self-paid test over the past three years provides a reasonable margin of safety against the risk of FDA non-approval.

Despite decades of progress in fighting it, cancer remains deadly. It is the second-leading cause of death in the United States, behind only heart disease.

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket Approval Application (PMA) Updated SYMPLIFY and REFLECTION Study Results to be Presented at the Early Detection of Cancer Conference (EDCC) Highlight Galleri Performance in Symptomatic and Veteran Populations, Respectively MENLO PARK, Calif. , Sept. 23, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the Galleri® multi-cancer early detection (MCED) test performance and safety from its registrational PATHFINDER 2 study at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Oct. 17-21, 2025.

Joint Venture Combines Advanced Plant Breeding Technology with Global Fruit Expertise to Deliver Consumer-Desired Traits Joint Venture Combines Advanced Plant Breeding Technology with Global Fruit Expertise to Deliver Consumer-Desired Traits

MENLO PARK, Calif. , Sept. 10, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum on Wednesday, Sep. 24 at 8:00 a.m.

GRAIL, Inc. (NASDAQ:GRAL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Robert Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi, everyone. I'm Yuko Oku, and I'm on the life science tools and diagnostics team at Morgan Stanley.

MENLO PARK, Calif. , Aug. 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 47,150 shares of GRAIL's common stock to 27 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pick-and-shovel' suppliers like Repligen, Illumina, and Twist Biosciences, which offer more stable financial prospects.

MENLO PARK, Calif. , Aug. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, Sep. 9 at 1:50 p.m.